NCT06325332View on ClinicalTrials.gov

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

Active, not recruitingOBSERVATIONAL
Enrollment

49,680

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Respiratory Syncytial Virus
Interventions
OTHER

Nirsevimab

Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection

Trial Locations (1)

94612

Kaiser Permanente Northern California: Site number 0001, Oakland

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY